Protocol Ledger

NCT06663098 · Phase II · RECRUITING

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Interventional Phase II clinical trial protocol NCT06663098 sponsored by Gruppo Oncologico Italiano di Ricerca Clinica in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-24 Enrollment: 142 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06663098
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)142 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06663098
Protocol FieldVerified Registry Value
NCT IdentifierNCT06663098
Consolidated Lead SponsorGruppo Oncologico Italiano di Ricerca Clinica
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment142 participants (ESTIMATED)
Registered Start Date2025-01-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06663098
Hospital Research SiteLocationSite Profile
IRCCS Ospedale San RaffaeleMilan, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI